IP Verse

Methods Of Treatment For Cystic Fibrosis

Patent No. EP3880197 (titled "Methods Of Treatment For Cystic Fibrosis") was filed by Vertex Pharmaceuticals Incorporated on Nov 13, 2019. The application was issued on Jul 2, 2025.

Patent Summary

A CFTR modulator compound, (14S)-8-[3-(2-{Dispiro[2.0.2.1]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ6-thia-3,9,11,18,23-pentaazatetracyclo [17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (Compound I), and pharmaceutical compositions containing the compound, for treating cystic fibrosis and other CFTR-mediated diseases. The compound is a CFTR modulator that can be used alone or in combination with other CFTR modulators to treat cystic fibrosis.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSNov 22, 2023D YOUNG
GENERICS UKNov 21, 2023TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3880197

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP19817037A
Filing Date
Nov 13, 2019
Status
Granted And Under Opposition
Jan 20, 2023
Publication Date
Jul 2, 2025
External Links
Slate, Register , Google Patents